News Release 

Earlier diagnosis and treatment assessment of tuberculosis achieved with pet/ct

Radiotracer provides valuable information to guide personalized therapy

Society of Nuclear Medicine and Molecular Imaging

Research presented at the Society of Nuclear Medicine and Molecular Imaging's 2019 Annual Meeting shows that molecular imaging with 18F-FDG positron emission tomography/computed tomography (PET/CT) can evaluate tuberculosis at the molecular level, effectively identifying diseased areas and guiding treatment for patients.

According to the World Health Association, tuberculosis is one of the top 10 causes of death worldwide. Although the disease is curable and preventable, in areas with high rates of tuberculosis, it contributes to significant morbidity, mortality and an increased risk of transmission from infected individuals. Tuberculosis most frequently involves the lungs; however involvement of tissues and organs other than the lungs is referred to as extra-pulmonary tuberculosis.

"Extra-pulmonary tuberculosis presents a particular challenge as the disease site is often not accessible for performing an invasive diagnosis. The physician thus relies on the clinical diagnosis for initiating treatment as well as deciding the duration of therapy, which can be difficult," said Bhagwant R. Mittal, MD, DNB, professor and department head of nuclear medicine at the Postgraduate Institute of Medical Education and Research in Chandigarh, India. "In our study, we aimed to evaluate the utility of 18F-FDG PET/CT in the initial diagnosis and response assessment of patients with extra-pulmonary tuberculosis."

Ninety-three patients with extra-pulmonary tuberculosis were prospectively enrolled in the study prior to the initiation of treatment. The patients underwent 18F-FDG PET/CT imaging as a baseline, and then received follow-up imaging after two months and after treatment completion. Follow-up scans were categorized into three groups: complete metabolic response (no abnormal lesions), residual disease (persistent lesions, but no new lesions) and disease progression (new lesions compared to the baseline scan).

In the baseline scans, 176 lesion sites were detected among the 93 study participants. The most common sites included the lymph nodes and central nervous system. Two month follow-up scans were performed on 47 patients, and 21.2 percent were classified as having complete metabolic response, 72.3 percent had residual disease and 6.4 percent were characterized as having disease progression. A final scan was conducted post-treatment and, of the 28 patients imaged, 28.6 percent had complete metabolic response, 53.6 percent of patients showed residual disease and 17.8 percent had disease progression. During the course of the study, 12.9 percent of patients died. Of these deaths, the patients who fell in the disease progression category had the highest mortality rate--60 percent.

"This study has the potential to change the way we manage tuberculosis patients. Our results show that 18F-FDG PET/CT provides a whole-body survey and identifies the disease sites in various organs and tissues in a single study. This helps to provide an early estimation of disease extent, and in suspected cases, helps to identify accessible biopsy sites for obtaining tissue diagnosis," Mittal said. "Further, follow-up scans can point towards response to treatment and thus suggest predict a more accurate outcome."


Abstract 227. "18F-FDG PET/CT in Extra-Pulmonary Tuberculosis - Role in Initial Evaluation and Response Assessment," Bhagwant R. Mittal, MD, DNB, Nuclear Medicine & PET, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Ashwin Singh Parihar, MBBS, Apurva Sood, MD, Harmandeep Singh, MD, Rajender Kumar, MD, and Anish Bhattacharya, MD, PhD, Nuclear Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India; Thomas Pascual, MD, Nuclear Medicine, International Atomic Energy Agency, Vienna, Austria; and Jamshed Bomanji, MD, Institute of Nuclear Medicine, London, United Kingdom. SNMMI's 66th Annual Meeting, June 22-25, 2019, Anaheim, CA.

To schedule an interview with the researchers, please contact David Harrison at (410) 804-1728 or All 2019 SNMMI Annual Meeting abstracts can be found online at

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

SNMMI's more than 16,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.